Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, , Seoul, Republic of Korea.
Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Hum Cell. 2023 May;36(3):894-907. doi: 10.1007/s13577-023-00872-z. Epub 2023 Feb 9.
Blood transfusions are now an essential part of modern medicine. Transfusable red blood cells (RBCs) are employed in various therapeutic strategies; however, the processes of blood donation, collection, and administration still involve many limitations. Notably, a lack of donors, the risk of transfusion-transmitted disease, and recent pandemics such as COVID-19 have prompted us to search for alternative therapeutics to replace this resource. Originally, RBC production was attempted via the ex vivo differentiation of stem cells. However, a more approachable and effective cell source is now required for broader applications. As a viable alternative, pluripotent stem cells have been actively used in recent research. In this review, we discuss the basic concepts related to erythropoiesis, as well as early research using hematopoietic stem cells ex vivo, and discuss the current trend of in vitro erythropoiesis using human-induced pluripotent stem cells.
输血现在是现代医学的重要组成部分。可输血的红细胞 (RBC) 被应用于各种治疗策略中;然而,献血、采集和管理的过程仍然存在许多限制。值得注意的是,由于缺乏献血者、输血传播疾病的风险,以及最近的 COVID-19 等大流行,我们一直在寻找替代疗法来替代这种资源。最初,人们试图通过干细胞的体外分化来产生 RBC。然而,为了更广泛的应用,现在需要一种更易于接近和有效的细胞来源。作为一种可行的替代方法,多能干细胞已在最近的研究中得到积极应用。在这篇综述中,我们讨论了与红细胞生成相关的基本概念,以及早期使用造血干细胞进行的体外研究,并讨论了使用人诱导多能干细胞进行体外红细胞生成的当前趋势。